Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEN-AZA + Modified BUCY Conditioning for High-Risk MDS and AML Allo-HSCT
NCT05823714Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Started Jan 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05823714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823714.